It benefits cancer therapy in many aspects, such as anti-proliferation (Kuo et al., 1994), anti-migration (Hueng et al., 2017), and inducing apoptosis (Li et al., 2015), in many mechanisms, including affecting lysosomal degradation (Hueng et al., 2017), targeting miR-33b (Zhang et al., 2015), modulating the ERK-JNK signaling pathway (Hwang et al., 2016; Joo et al., 2017), activating p38 MAPK (Baik et al., 2016), and so on. Here, MAPK8 is linked to cancer.